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1. INTRODUCTION {#phy214440-sec-0001}
===============

Hypertension is a major contributor to morbidity and mortality worldwide. In the United States, age‐matched prevalence of hypertension from 2015 to 2016 was 46% of the population, and the absolute burden of hypertension has increased (Dorans, Mills, Liu, & He, [2018](#phy214440-bib-0012){ref-type="ref"}; Virani et al., [2020](#phy214440-bib-0071){ref-type="ref"}). Data from the National Health and Nutrition Examination Survey (NHANES) from 2009 to 2012 indicate that only slightly over half (54.1%) of all those with hypertension were "controlled," or adequately managed on their current medical therapy by the most recent blood pressure (BP) guidelines. The American Heart Association 2020 Update reports that the death rate attributable to hypertension rose 25.7% in the decade from 2007 to 2017 and the number of actual deaths increased by 56.1% (Virani et al., [2020](#phy214440-bib-0071){ref-type="ref"}). The pathogenesis of hypertension is multifactorial, and likely differs on a patient‐to‐patient basis (Oparil, Zaman, & Calhoun, [2003](#phy214440-bib-0043){ref-type="ref"}).

Epidemiologic data show sex differences in the prevalence of hypertension. Before 45 years of age, there is a higher prevalence of hypertension men than women, whereas after 65 years of age, prevalence increases in women. From 45 to 64 years of age, there is no difference in prevalence between the sexes (Mozaffarian et al., [2016](#phy214440-bib-0040){ref-type="ref"}; Virani et al., [2020](#phy214440-bib-0071){ref-type="ref"}). However, these differences are not reflected in current guidelines for BP management, likely due to a lack of evidence regarding etiology, progression, and treatment relevant to sex‐specific hypertension, while specific recommendations based on age and race do appear (Whelton et al., [2018](#phy214440-bib-0074){ref-type="ref"}). While subgroup analysis from the SPRINT trial demonstrated no significant difference in outcomes for men and women (Foy et al., [2018](#phy214440-bib-0017){ref-type="ref"}), this is likely due to the gross underrepresentation of women compared to men in this trial (36% women, 64% men), which is a common and persistent issue in many clinical trials. Additional rationale for the discrepancy can be found in the analysis by Delles and Currie ([2018](#phy214440-bib-0011){ref-type="ref"}).

Sex differences are also observed in several animal models of hypertension, including the angiotensin II‐infusion model in mice and rats, the Dahl S rat, and the L‐NAME rat infusion model (Hinojosa‐Laborde, Lange, & Haywood, [2000](#phy214440-bib-0024){ref-type="ref"}; Ouchi, Share, Crofton, Iitake, & Brooks, [1987](#phy214440-bib-0045){ref-type="ref"}; Pollow et al., [2014](#phy214440-bib-0049){ref-type="ref"}; Sainz et al., [2004](#phy214440-bib-0058){ref-type="ref"}; Xue et al., [2009](#phy214440-bib-0075){ref-type="ref"}; Xue, Pamidimukkala, & Hay, [2005](#phy214440-bib-0076){ref-type="ref"}). While many studies focus on the contributions of chromosomal factors and gonadal hormones to these differences (Ji et al., [2010](#phy214440-bib-0027){ref-type="ref"}; Sainz et al., [2004](#phy214440-bib-0058){ref-type="ref"}; Xue et al., [2009](#phy214440-bib-0075){ref-type="ref"}), additional mechanisms are also being studied, such as differences in immune cell infiltration (Gillis & Sullivan, [2016](#phy214440-bib-0019){ref-type="ref"}; Pollow et al., [2014](#phy214440-bib-0049){ref-type="ref"}). Nevertheless, studies directly examining the molecular mechanisms underlying sex differences in hypertension are needed to further elucidate both the etiology and potential therapeutic targets.

Oxidative stress produced by inflammation and immune cell infiltration is a known contributor to both hypertension and kidney disease (Meng, Nikolic‐Paterson, & Lan, [2014](#phy214440-bib-0039){ref-type="ref"}; Rodriguez‐Iturbe, Pons, & Johnson, [2017](#phy214440-bib-0054){ref-type="ref"}). Specifically, it seems that the interrelated mechanisms of inflammation, immune cell infiltration and activation, oxidative stress, and remodeling contribute to a self‐perpetuating cycle of damage (Vaziri & Rodriguez‐Iturbe, [2006](#phy214440-bib-0070){ref-type="ref"}). Immune cells are a source of proinflammatory cytokines and profibrotic chemokines that lead to extracellular remodeling and collagen deposition, and oxidative stress acts as a chemoattractant for immune cells in addition to causing direct cellular damage. Oxidative stress is shown to increase renal vascular resistance (RVR), which is improved by addition of an antioxidant superoxide dismutase (SOD) mimetic (Schnackenberg, Welch, & Wilcox, [1998](#phy214440-bib-0060){ref-type="ref"}; Zou, Li, & Cowley, [2001](#phy214440-bib-0080){ref-type="ref"}). Improvement in RVR seems to be mediated through the nitric oxide (NO) pathway, since inhibition of NO production with L‐NAME prevents the antihypertensive effect of the SOD mimetic (Schnackenberg et al., [1998](#phy214440-bib-0060){ref-type="ref"}). The changes in RVR in response to oxidative stress also exert an influence on the nearby endothelial cell phenotypes, inducing cellular damage, changes in gene expression transcription, and adhesion molecule expression, ultimately leading to microvascular dysfunction (Li & Shah, [2004](#phy214440-bib-0035){ref-type="ref"}; True, Rahman, & Malik, [2000](#phy214440-bib-0068){ref-type="ref"}).

Human studies and animal models of hypertension have demonstrated increased oxidative stress and decreased antioxidant mechanisms (Beswick, Dorrance, Leite, & Webb, [2001](#phy214440-bib-0004){ref-type="ref"}; Grunfeld et al., [1995](#phy214440-bib-0021){ref-type="ref"}; Kumar & Das, [1993](#phy214440-bib-0033){ref-type="ref"}; Meng, Cason, Gannon, Racusen, & Manning, [2003](#phy214440-bib-0037){ref-type="ref"}; Pedro‐Botet, Covas, Martin, & Rubies‐Prat, [2000](#phy214440-bib-0047){ref-type="ref"}; Russo et al., [1998](#phy214440-bib-0057){ref-type="ref"}; Schnackenberg et al., [1998](#phy214440-bib-0060){ref-type="ref"}). While levels of reactive oxygen species (ROS) have varied in human studies, several studies found consistent decreases in the antioxidant enzyme SOD in hypertensive patients compared to controls (Kumar and Das, ([1993](#phy214440-bib-0033){ref-type="ref"}); Pedro‐Botet et al., [2000](#phy214440-bib-0047){ref-type="ref"}; Russo et al., [1998](#phy214440-bib-0057){ref-type="ref"}). In addition to direct cellular damage, ROS contributes to disease and damage through secondary mechanisms such as inactivation of NO (Beckman & Koppenol, [1996](#phy214440-bib-0003){ref-type="ref"}). Decreases in NO have been noted in hypertensive patients with a concurrent increase in ROS, which were returned to normal after achieving BP control (Kumar & Das, [1993](#phy214440-bib-0033){ref-type="ref"}). Furthermore, low levels of NO have been shown to act in a signaling capacity, increasing expression of antioxidants (Keller et al., [2003](#phy214440-bib-0030){ref-type="ref"}), and protecting against oxidative damage and fibrosis (Dreieicher et al., [2009](#phy214440-bib-0014){ref-type="ref"}; Pleskova et al., [2006](#phy214440-bib-0048){ref-type="ref"}; Schaefer et al., [2003](#phy214440-bib-0059){ref-type="ref"}). Upregulation or maintenance of endothelial NO synthase (NOS3) has been suggested as one mechanism for renal protection produced by the statin and β‐blocker drug classes (Kobayashi et al., [2008](#phy214440-bib-0032){ref-type="ref"}; Mason et al., [2006](#phy214440-bib-0036){ref-type="ref"}; Zhou, Jaimes, & Raij, [2004](#phy214440-bib-0078){ref-type="ref"}; Zhou, Schuman, Jaimes, & Raij, [2008](#phy214440-bib-0079){ref-type="ref"}). While clinical trials with nonspecific antioxidant therapies have largely failed to show benefits in hypertension, more specifically targeted therapies may show promise if the contributory mechanism can be identified. For example, if oxidative stress is found to significantly contribute to the etiology of hypertension in a single subgroup, such as a single sex, these therapies can be targeted to the group that will achieve the highest response rate.

Oxidative stress has also been shown to contribute to the pathogenesis of CKD in humans. Markers of oxidative stress have been shown to increase significantly with severity of CKD and are reduced by hemodialysis (Dounousi et al., [2006](#phy214440-bib-0013){ref-type="ref"}; Karamouzis et al., [2008](#phy214440-bib-0029){ref-type="ref"}). Yilmaz et al. ([2006](#phy214440-bib-0077){ref-type="ref"}) showed higher levels of markers of oxidative stress and lower levels of antioxidants in patients with CKD as compared to controls, as well as a negative correlation between markers of oxidative stress and glomerular filtration rate (GFR). Furthermore, the expression of extracellular superoxide dismutase (EC SOD), a key antioxidant enzyme, is significantly decreased in renal samples of patients with fibrotic proteinuric CKD (Tan et al., [2015](#phy214440-bib-0062){ref-type="ref"}). Meta‐analysis of clinical trials using antioxidants in patients on dialysis or with CKD demonstrated potential for improvement of creatinine clearance and reduced development of end‐stage kidney disease, though all studies involved were relatively small (Jun et al., [2012](#phy214440-bib-0028){ref-type="ref"}).

The Dahl SS/Jr rat is an established model of salt‐sensitive hypertension that develops hypertension and renal injury with age in the absence of high salt. The progression of hypertension and renal injury in this strain on a low salt (0.3% NaCl) diet provides an avenue for the study of age‐related disease progression without the excess mortality present on a high salt diet (Cicila et al., [1997](#phy214440-bib-0006){ref-type="ref"}, [2009](#phy214440-bib-0007){ref-type="ref"}; Garrett, Dene, & Rapp, [2003](#phy214440-bib-0018){ref-type="ref"}). The use of salt‐sensitive animals is also reflective of the affected population, since a majority of individuals with hypertension are known to be at least somewhat salt‐sensitive (Elijovich et al., [2016](#phy214440-bib-0015){ref-type="ref"}). The purpose of this study was to test the hypothesis that male Dahl S hypertensive rats have accelerated renal injury and dysfunction compared to females and to determine the contributions of the nitric oxide pathway and oxidative stress to these differences.

2. METHODS {#phy214440-sec-0002}
==========

2.1. Animals {#phy214440-sec-0003}
------------

Dahl salt‐sensitive (SS/Jr) rats were obtained from the colony maintained by Dr. Michael Garrett at the University of Mississippi Medical Center. All rats were fed normal chow (TD7034, 0.3% NaCl, Harlan Teklad, Madison, WI) and water ad libitum on a 12‐hr light/dark cycle. Development of hypertension in Dahl SS/Jr rats on a 0.3% NaCl diet has been previously established, and higher content salt diets act only to hasten the onset and increase mortality (Cicila et al., [1997](#phy214440-bib-0006){ref-type="ref"}, [2009](#phy214440-bib-0007){ref-type="ref"}; Garrett et al., [2003](#phy214440-bib-0018){ref-type="ref"}; Rapp & Dene, [1985](#phy214440-bib-0051){ref-type="ref"}). Male and female rats were mated in nonconsanguineous groups, and the presence of sperm in a vaginal swab was indicative of gestational day one. Lactating dams and pups were on normal chow for the duration of the study, and pups were weaned at 4 weeks of age. Measurements were made and tissues collected on separate groups of offspring at 3 and 6 months of age. One male and one female pup per litter were maintained to each time point with up to three same‐sex cagemates. Animals were assessed regularly by laboratory and animal facility staff for signs of illness, cachexia, or other health concerns and were removed from the studies if necessary. All experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were monitored by the University of Mississippi Medical Center Institutional Animal Care and Use Committee.

2.2. Systolic blood pressure measurements {#phy214440-sec-0004}
-----------------------------------------

Systolic BP measurements were obtained using the volumetric pressure recording tail cuff method (CODA 8‐channel system, Kent Scientific Corp., Torrington, CT). Animals were trained in restraints alone followed by training in restraints on the heated platform before obtaining sets of no less than five valid measurements each on two consecutive days. Training and measurements took place in the same room adjacent to animal housing before noon on each respective day. Measurements for each animal were averaged to obtain final BP measurement.

2.3. Urinary Measurements {#phy214440-sec-0005}
-------------------------

Rats were placed in metabolic cages adjacent to their original housing for 24‐hr urine collection prior to tissue harvest. Urinary protein excretion was determined by Bradford Assay (Bio‐Rad Laboratories). Urinary excretion rates of KIM‐1 (R&D Systems, Minneapolis, MN) and nephrin (ABclonal, Woburn, MA) were quantified via commercially available ELISA assays. Urinary nitrate/nitrite excretion (NOx) was measured using a colorimetric assay (Cayman Chemical, Ann Arbor, MI). Urinary thiobarbituric acid reactive substances (TBARS) were measured via a chemical assay (R&D Systems, Minneapolis, MN).

2.4. Tissue collection {#phy214440-sec-0006}
----------------------

When rats reached either 3 or 6 months of age, subgroups were anesthetized using inhaled isoflurane anesthesia (5% for induction, 2%--3% for maintenance, Piramal Healthcare). A terminal blood sample was obtained from the abdominal aorta into heparinized syringes, and the organs were subsequently perfused blood‐free with saline. Euthanasia was performed by excising the heart. The kidneys were removed, dissected into cortical and medullary regions, and snap frozen in liquid nitrogen for later analysis.

2.5. Renal histological analysis {#phy214440-sec-0007}
--------------------------------

A cross‐section of the left kidney of all rats was fixed in 10% formalin, paraffin embedded, cut into 4 µm sections, and stained with Masson\'s trichrome stain. Glomerular injury was assessed on a scale from 0 (normal) to 4 (severe) for 25 glomeruli per sample as previously described (Raij, Azar, & Keane, [1984](#phy214440-bib-0050){ref-type="ref"}).

2.6. Creatinine clearance measurements {#phy214440-sec-0008}
--------------------------------------

Terminal blood samples were centrifuged, and plasma was isolated. Creatinine concentrations were measured in both urine and plasma samples (Vet Axcel Chemistry Analyzer, Alfa Wasserman, West Caldwell, NJ) and then used to calculate creatinine clearance for each animal.

2.7. Western blots {#phy214440-sec-0009}
------------------

Renal cortices were isolated from right and left kidneys collected at euthanasia. Kidney sections were homogenized in lysis buffer (Tris 20 mM, EDTA 5 mM, EGTA 10 mM, sodium orthovanadate 1 mM, Triton X‐100 1%, sodium pyrophosphate 2.5 mM, B‐glycerophosphate 1 mM, DTT 2 mM, PMSF 0.1 mg/ml, leupeptin 0.01 mg/ml, aprotinin 0.01 mg/ml) using the Next Advance Bullet Blender. Total protein concentration for each sample was determined using a DC protein assay (Bio‐Rad Laboratories). Homogenized samples were standardized by their protein concentrations (200 μg per lane), separated by electrophoresis (140 V until fully separated, 4%--15% TGX Stain‐Free Precast gel, Bio‐Rad Laboratories), and then transferred to nitrocellulose membranes (Bio‐Rad Trans‐Blot Turbo). Gels and membranes were imaged (ChemiDoc MP Imaging System and Image Lab 3.0 Software, Bio‐Rad Laboratories) to determine transfer efficiency/uniformity and equal loading. Each membrane was incubated overnight with the primary antibody (rabbit anti‐Cu/Zn SOD \[1:2000\], Enzo Life Sciences SOD‐101; rabbit anti‐Mn SOD \[1:2000\], Enzo Life Sciences SOD‐111; rabbit anti‐EC SOD \[1:1000\], Enzo Life Sciences SOD‐106, antibodies previously validated by Ho et al. ([2016](#phy214440-bib-0025){ref-type="ref"})), at 4°C on a rocking plate. Membranes were then incubated with a fluorescent secondary antibody (goat anti‐rabbit \[1:3000\] for Cu/Zn and Mn SOD, \[1:2000\] for EC SOD, Bio‐Rad Laboratories StarBright Blue700) for 1 hr at room temperature. Bands were quantified by densitometry using the Image Lab 3.0 Software (Bio‐Rad Laboratories). After subtraction of background, protein abundance was calculated as integrated optical density of the protein of interest, factored for total protein loading for each sample.

2.8. Targeted RNA sequencing {#phy214440-sec-0010}
----------------------------

Expression analysis was performed on genes involved in inflammation, glomerular function, renal injury, and reactive oxygen species. RNA was isolated from kidney using an automated KingFisher™ Flex nucleic acid system along with a KingFisher™ Pure RNA Kit. RNA was evaluated for quantity (Nanodrop One and Qubit Fluorimeter) and quality using Qiagen QIAxcel Advanced system. The Illumina DesignStudio application (<http://designstudio.illumina.com/>) was utilized to design custom amplicons across exon‐intron boundaries of target genes (*n* = 32 gene with 1--2 probes per gene). The gene target/probes that were designed/used are listed in Tables [1](#phy214440-tbl-0001){ref-type="table"} and [2](#phy214440-tbl-0002){ref-type="table"}. Based on the DesignStudio output, the TruSeq Targeted RNA Custom Panel Kit was ordered and subsequently utilized to prepare a library for collected RNA samples. The Illumina MiSeq platform allows for analysis of pooled libraries \[e.g., *n* = 96--384 RNA samples) to be processed at a single time as individual samples will have a unique "barcode." Libraries were sequenced on Illumina MiSeq using MiSeq Reagent Kit v2 (150 cycle). Sequencing reads were demultiplexed and aligned to rn6 genome assembly using RNA Amplicon Application (along with custom panel manifest) available on Illumina BaseSpace Computing Platform (<http://basespace.illumina.com/>). Aligned reads for each gene were normalized to count per million for downstream analysis.

###### 

Gene targets and corresponding proteins quantified by targeted RNA sequencing as described in methods

  Gene Identifier   Protein
  ----------------- ------------------------------------------------------------
  agtr1a            Angiotensin II Receptor, type 1A
  CAT               Catalase
  col3a1            Collagen Type III Alpha 1 chain
  edn1              Endothelin−1
  ednra             Endothelin Receptor type A
  endrb             Endothelin Receptor type B
  GPX2              Glutathione Peroxidase 2
  GSS               Glutathione Synthetase
  hmox1             Heme Oxygenase 1
  hmox2             Heme Oxygenase 2
  hif3a             Hypoxia‐Inducible Factor 3 Alpha
  IL10              Interleukin 10
  IL17A             Interleukin 17A
  IL6               Interleukin 6
  HAVCR1            Hepatitis A Virus Cellular Receptor 1
  NOX4              NADPH Oxidase 4
  NPHS1             Nephrin
  LCN2              Lipocalin 2
  NOs2              Nitric Oxide Synthase 2, inducible nitric oxide synthase
  NOS3              Nitric Oxide Synthase 3, endothelial nitric oxide synthase
  pde5a             Phosphodiesterase 5A
  nphs2             Podocin
  prkg2             cGMP‐dependent protein kinase G
  atp6ap2           V‐type proton ATPase
  s100a4            S100 calcium binding protein A4
  sod1              Superoxide Dismutase 1
  sod2              Superoxide Dismutase 2
  sod3              Superoxide Dismutase 3
  tgfb1             Tumor Growth Factor β1
  timp1             TIMP metallopeptidase inhibitor 1
  tnf               Tumor necrosis factor
  vim               Vimentin
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###### 

Gene targets and probes used in targeted RNA sequencing as described in methods

  Gene Name   Transcript ID   Left Exon   Right Exon   Species               Chromosome   Start         End
  ----------- --------------- ----------- ------------ --------------------- ------------ ------------- -------------
  Agtr1a      NM_030985       1           0            *Rattus norvegicus*   chr17        40,684,884    40,675,481
  Agtr1a      NM_030985       2           1            *Rattus norvegicus*   chr17        40,675,458    40,631,259
  Cat         NM_012520       6           7            *Rattus norvegicus*   chr3         88,672,303    88,672,855
  Cat         NM_012520       9           10           *Rattus norvegicus*   chr3         88,680,122    88,683,020
  Col3a1      NM_032085       13          14           *Rattus norvegicus*   chr9         44,299,016    44,299,719
  Col3a1      NM_032085       49          50           *Rattus norvegicus*   chr9         44,316,672    44,317,443
  Edn1        NM_012548       2           1            *Rattus norvegicus*   chr17        28,307,715    28,306,343
  Edn1        NM_012548       4           3            *Rattus norvegicus*   chr17        28,305,981    28,304,545
  Ednra       NM_012550       2           3            *Rattus norvegicus*   chr19        32,081,838    32,095,813
  Ednra       NM_012550       6           7            *Rattus norvegicus*   chr19        32,103,022    32,105,026
  Ednrb       NM_017333       3           2            *Rattus norvegicus*   chr15        87,896,604    87,893,678
  Ednrb       NM_017333       2           1            *Rattus norvegicus*   chr15        87,897,524    87,896,651
  Gpx2        NM_183403       1           0            *Rattus norvegicus*   chr6         99,375,916    99,373,055
  Gss         NM_012962       5           4            *Rattus norvegicus*   chr3         146,072,936   146,072,201
  Gss         NM_012962       12          11           *Rattus norvegicus*   chr3         146,059,093   146,058,026
  Hmox1       NM_012580       2           3            *Rattus norvegicus*   chr19        13,966,589    13,968,156
  Hmox1       NM_012580       1           2            *Rattus norvegicus*   chr19        13,965,273    13,966,155
  Hmox2       NM_024387       2           1            *Rattus norvegicus*   chr10        10,918,090    10,917,095
  Hmox2       NM_024387       1           0            *Rattus norvegicus*   chr10        10,929,339    10,918,153
  Hif3a       NM_022528       14          13           *Rattus norvegicus*   chr1         77,379,020    77,377,608
  Hif3a       NM_022528       10          9            *Rattus norvegicus*   chr1         77,395,493    77,384,150
  Il10        NM_012854       3           4            *Rattus norvegicus*   chr13        43,956,466    43,957,558
  Il10        NM_012854       0           1            *Rattus norvegicus*   chr13        43,954,037    43,954,961
  Il17a       NM_001106897    0           1            *Rattus norvegicus*   chr9         19,455,037    19,456,177
  Il6         NM_012589       3           2            *Rattus norvegicus*   chr4         459,586       458,654
  Il6         NM_012589       4           3            *Rattus norvegicus*   chr4         458,568       457,278
  Havcr1      NM_173149       5           6            *Rattus norvegicus*   chr10        31,851,805    31,853,749
  Havcr1      NM_173149       3           4            *Rattus norvegicus*   chr10        31,844,938    31,848,575
  Nox4        NM_053524       16          17           *Rattus norvegicus*   chr1         143,590,456   143,603,070
  Nox4        NM_053524       11          12           *Rattus norvegicus*   chr1         143,506,962   143,564,685
  Nphs1       NM_022628       27          28           *Rattus norvegicus*   chr1         85,439,246    85,442,407
  Nphs1       NM_022628       19          20           *Rattus norvegicus*   chr1         85,427,263    85,430,136
  Lcn2        NM_130741       1           0            *Rattus norvegicus*   chr3         11,514,593    11,514,017
  Lcn2        NM_130741       2           1            *Rattus norvegicus*   chr3         11,513,935    11,512,859
  Nos2        NM_012611       25          26           *Rattus norvegicus*   chr10        65,070,187    65,072,223
  Nos2        NM_012611       8           9            *Rattus norvegicus*   chr10        65,052,926    65,054,621
  Nos3        NM_021838       13          12           *Rattus norvegicus*   chr4         6,170,899     6,166,281
  Nos3        NM_021838       23          22           *Rattus norvegicus*   chr4         6,160,552     6,159,872
  Pde5a       NM_133584       7           8            *Rattus norvegicus*   chr2         219,483,379   219,484,314
  Pde5a       NM_133584       20          21           *Rattus norvegicus*   chr2         219,547,581   219,550,380
  Nphs2       NM_130828       6           7            *Rattus norvegicus*   chr13        71,307,268    71,308,198
  Nphs2       NM_130828       3           4            *Rattus norvegicus*   chr13        71,302,117    71,303,654
  Prkg2       NM_013012       11          12           *Rattus norvegicus*   chr14        11,946,797    11,969,486
  Prkg2       NM_013012       17          18           *Rattus norvegicus*   chr14        12,002,461    12,004,842
  Atp6ap2     NM_001007091    3           2            *Rattus norvegicus*   chrX         22,283,504    22,276,529
  Atp6ap2     NM_001007091    8           7            *Rattus norvegicus*   chrX         22,272,699    22,265,189
  S100a4      NM_012618       0           1            *Rattus norvegicus*   chr2         182,885,080   182,886,301
  S100a4      NM_012618       1           2            *Rattus norvegicus*   chr2         182,886,396   182,887,116
  Sod1        NM_017050       3           2            *Rattus norvegicus*   chr11        29,812,746    29,811,996
  Sod1        NM_017050       2           1            *Rattus norvegicus*   chr11        29,814,314    29,812,763
  Sod2        NM_017051       4           3            *Rattus norvegicus*   chr1         41,865,039    41,864,427
  Sod2        NM_017051       3           2            *Rattus norvegicus*   chr1         41,868,148    41,865,155
  Sod3        NM_012880       1           0            *Rattus norvegicus*   chr14        63,387,093    63,383,027
  Tgfb1       NM_021578       1           2            *Rattus norvegicus*   chr1         80,898,707    80,900,377
  Tgfb1       NM_021578       5           6            *Rattus norvegicus*   chr1         80,910,208    80,910,748
  Timp1       NM_053819       2           1            *Rattus norvegicus*   chrX         12,546,228    12,544,383
  Timp1       NM_053819       5           4            *Rattus norvegicus*   chrX         12,543,722    12,542,718
  Tnf         NM_012675       0           1            *Rattus norvegicus*   chr20        3,661,297     3,661,856
  Tnf         NM_012675       3           3            *Rattus norvegicus*   chr20        3,662,950     3,663,001
  Vim         NM_031140       7           8            *Rattus norvegicus*   chr17        87,854,627    87,855,433
  Vim         NM_031140       4           5            *Rattus norvegicus*   chr17        87,852,234    87,853,124
  Gapdh       NM_017008       2           1            *Rattus norvegicus*   chr4         161,285,787   161,283,854
  Pgk1        NM_053291       2           3            *Rattus norvegicus*   chrX         94,331,155    94,331,330
  Pgk1        NM_053291       7           8            *Rattus norvegicus*   chrX         94,336,859    94,338,987
  HPRT1       NM_012583       7           8            *Rattus norvegicus*   chrX         139,960,354   139,961,091
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2.9. Statistical analysis {#phy214440-sec-0011}
-------------------------

All data are presented as mean ± SE. Statistical analyses were performed by two‐way ANOVA followed by Tukey\'s post hoc analysis using GraphPad Prism 8.0 (San Diego, CA). Glomerulosclerosis scoring was analyzed by the Mann--Whitney test. Means were considered significantly different if *p* \< .05.

3. RESULTS {#phy214440-sec-0012}
==========

3.1. Systolic blood pressure does not differ between sexes in Dahl S rats {#phy214440-sec-0013}
-------------------------------------------------------------------------

Although studies in other rat models of hypertension exhibit significant BP differences between sexes (Hinojosa‐Laborde et al., [2000](#phy214440-bib-0024){ref-type="ref"}), systolic BP was similar (*p* \> .05) between sexes in the Dahl SS/Jr rat at 3 and 6 months of age (Table [3](#phy214440-tbl-0003){ref-type="table"}).

###### 

Systolic BP does not differ significantly between sexes or over time (*p*, sex = 0.9, *p*, age = 0.06, *p*, interaction = 0.4) *n* = 6‐12/group

+-------------+----------+----------+
| Systolic BP | 3 months | 6 months |
|             |          |          |
| mmHg        |          |          |
+=============+==========+==========+
| Male        | 159 ± 9  | 180 ± 4  |
+-------------+----------+----------+
| Female      | 165 ± 3  | 173 ± 12 |
+-------------+----------+----------+

John Wiley & Sons, Ltd

3.2. Female Dahl S rats exhibit maintenance of renal function with attenuated age‐related progression of renal injury compared to males {#phy214440-sec-0014}
---------------------------------------------------------------------------------------------------------------------------------------

Although no significant difference exists in systolic BP, females exhibited significantly lower urinary protein excretion at 6 months of age compared to males (Figure [1](#phy214440-fig-0001){ref-type="fig"}), indicating less damage to the glomerular filtration barrier, as well as less glomerulosclerosis (Figure [2](#phy214440-fig-0002){ref-type="fig"}). This degree of injury was further investigated by using nephrin as a marker of glomerular injury and kidney injury marker‐1 (KIM‐1) as a marker of tubular injury. While no significant sex differences were found in excretion of nephrin at either time point, KIM‐1 excretion was significantly lower in females as compared to males at 6 months of age, in congruency with the proteinuria data (Figure [3](#phy214440-fig-0003){ref-type="fig"}). Females also demonstrated no change in creatinine clearance over time, showing no significant difference from 3 to 6 months of age (*p* = .2), while males showed a significant decline over this time period (*p* \< .0001). At 3 months, creatinine clearance of females was significantly lower than that of males; however, at 6 months, females were significantly higher due to the lack of change with time compared to the decline seen in male rats (Figure [4](#phy214440-fig-0004){ref-type="fig"}).

![Twenty‐four‐hour protein excretion increases significantly in male Dahl S rats from 3 to 6 months of age but does not in age‐matched female offspring. Proteinuria is also significantly lower in female Dahl S rats at 6 months of age as compared to age‐matched males. n/group: 3 mo male = 13; 3 months female = 12; 6 months male = 13; 6 months female = 8, \**p* \< .05 versus same age male, †*p* \< .05 versus same sex at 3 mo. Analysis performed using two‐way ANOVA followed by Tukey\'s post hoc test](PHY2-8-e14440-g001){#phy214440-fig-0001}

![Histological glomerular injury is not different between sexes. (a) Quantification by glomerulosclerosis scoring. (b--e), representative images. (b) Three‐month male, *n* = 5. (c) Three‐month female, *n* = 6. (d) Six‐month male, *n* = 8. (e) Six‐month female, *n* = 8. Analysis performed using Mann--Whitney test](PHY2-8-e14440-g002){#phy214440-fig-0002}

![Age‐related advancement of renal injury is moderately attenuated in female offspring. KIM‐1 excretion is significantly lower than that of age‐matched males at 6 months of age, indicating attenuated advancement of renal injury with age. Nephrin excretion is no different between sexes at 3 or 6 months of age. (a) Kidney injury marker‐1 (KIM‐1) measured in urine, n/group: 3 mo male = 8; 3 mo female = 7; 6 mo male = 7; 6 mo female = 8. (\**p* \< .05 versus. same age male, **†** *p* \< .05 versus. same sex at 3 mo). (b) Nephrin measured in urine, n/group: 3 months male = 4; 3 mo female = 6; 6 months male = 8; 6 months female = 8. Analysis performed using two‐way ANOVA followed by Tukey\'s post hoc test](PHY2-8-e14440-g003){#phy214440-fig-0003}

![Creatinine clearance is significantly lower in female Dahl S rats at 3 months of age, but is not statistically different at 6 months of age as compared to three months of age (*p* = .2), whereas that of male Dahl S rats decreases significantly (*p* = .01), n/group: 3 months male = 8; 3 months female = 5; 6 months male = 13; 6 months female = 6. (*p*, interaction age x sex \< 0.0001, \**p* \< .05 vs. same age male, †*p* \< .0001 vs. same sex at 3 months). Analysis performed using two‐way ANOVA followed by Tukey\'s post hoc test](PHY2-8-e14440-g004){#phy214440-fig-0004}

3.3. Female Dahl S rats exhibit significantly higher EC SOD mRNA but no difference in protein expression of SOD isoforms or TBARS excretion {#phy214440-sec-0015}
-------------------------------------------------------------------------------------------------------------------------------------------

We employed targeted RNA sequencing to explore potential mechanisms for the exacerbated renal injury observed in male Dahl S rats (Table [4](#phy214440-tbl-0004){ref-type="table"}). While no sex differences were apparent in most genes, this analysis revealed a significant upregulation of EC SOD (SOD3), the extracellular form of the antioxidant enzyme superoxide dismutase, in female Dahl S rats as compared to males (Figure [5a](#phy214440-fig-0005){ref-type="fig"}). However, it seems that this difference is isolated to a single isoform, as no differences exist in transcription of Cu/Zn SOD, the cytoplasmic form of the enzyme, or Mn SOD, the mitochondrial form, at either time point (Figure [5b‐c](#phy214440-fig-0005){ref-type="fig"}). To further explore the potential role of SOD in the observed renoprotection, we sought to confirm differences at the protein level and determine if there were measurable differences in oxidative stress markers. The difference in transcription levels of EC SOD are not supported by protein expression as determined by western blot, which shows equivocal levels of all isoforms between sexes at each time point (Figure [6a‐c](#phy214440-fig-0006){ref-type="fig"}). Furthermore, no sex differences were seen in urinary TBARS at either 3 or 6 months of age (Figure [7](#phy214440-fig-0007){ref-type="fig"}).

###### 

Normalized counts of all genes studied via targeted RNA sequencing. (Und = undetectable, \**p* \< .05 vs. age‐matched male)

  Gene      3 mo‐Male   3 mo‐Female   6 mo‐Male   6 mo‐Female   *p*, age   *p*, sex      interaction
  --------- ----------- ------------- ----------- ------------- ---------- ------------- -------------
  Agtr1a    0.015       0.020         0.016       0.023         .7         .2            0.9
  cat       1.041       1.039         1.723       0.774         .4         .06           0.06
  col3a1    0.104       0.087         0.121       0.051         .6         **.04**       0.2
  edn1      0.007       0.005         0.012       0.003         .6         .07           0.3
  ednra     0.001       0.002         0.001       0.001         .5         .7            0.7
  ednrb     0.059       0.079         0.047       0.064         .08        **.02**       0.9
  gpx2      0.009       0.018         0.025       0.012         .2         .6            **0.02**
  gss       0.595       0.821         0.605       0.605         .4         .3            0.3
  hmox1     0.007       0.006         0.005       0.005         .2         .8            1.0
  hmox2     Und         Und           Und         Und           ---        ---           ---
  hif3a     0.000       0.001         0.003       0.001         .2         .5            0.3
  IL10      Und         Und           Und         Und           ---        ---           ---
  il17a     Und         Und           Und         Und           ---        ---           ---
  IL6       Und         Und           Und         Und           ---        ---           ---
  havcr1    0.023       0.048         0.057       0.024         .8         .8            0.08
  nox4      0.151       0.097         0.209       0.132         .4         .2            0.8
  nphs1     0.027       0.035         0.011       0.023         .2         .5            0.3
  lcn2      0.009       0.020         0.017       0.016         .7         .5            0.3
  NOs2      Und         Und           Und         Und           ---        ---           ---
  NOS3      0.005       0.007         0.003       0.005         .2         .2            1.0
  pde5a     0.005       0.022         0.013       0.012         .8         .08           0.06
  nphs2     0.103       0.097         0.073       0.079         .5         .7            0.5
  prkg2     Und         Und           Und         Und           ---        ---           ---
  atp6ap2   0.113       0.162         0.167       0.178         **.04**    .07           0.2
  s100a4    0.031       0.028         0.040       0.046         .2         .9            0.7
  sod1      2.609       2.156         3.031       2.348         .4         .1            0.7
  sod2      0.627       0.542         0.778       0.691         **.03**    .2            1.0
  sod3      0.353       1.369\*       0.407       1.290\*       .7         **\<.0001**   0.5
  tgfb1     0.019       0.023         0.021       0.018         .7         .9            0.5
  timp1     0.033       0.042         0.036       0.031         .6         .8            0.3
  tnf       Und         Und           Und         Und           ---        ---           ---
  vim       0.141       0.173         0.144       0.124         .4         0.8           0.3

Bold indicates *p* \< .05.
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![RNA expression of superoxide dismutase isoforms in the renal cortex. Expression levels of Cu/Zn SOD and Mn SOD remain relatively stable in both sexes at both time points, with expression of Mn SOD increasing significantly with age. However, RNA expression of EC SOD in the renal cortex is significantly higher in female Dahl S rats at both 3 and 6 months of age, n/group: 3 months male = 4; 3 months female = 5; 6 months male = 4; 6 months female = 4. (a) SOD3, EC SOD, extracellular isoform, (*p*, sex \< .0001, \**p* \< . 5 vs. same age male). (b) SOD1, Cu/Zn SOD, cytoplasmic isoform. (c) SOD2, Mn SOD, mitochondrial isoform, (†*p*, age = .03). Analysis performed using two‐way ANOVA followed by Tukey\'s post hoc test](PHY2-8-e14440-g005){#phy214440-fig-0005}

![Protein expression of superoxide dismutase isoforms in the renal cortex. Protein loading was controlled by correcting for total protein present in each sample as measured by stain‐free gel imaging, n/group: 3 months male = 6; 3 months female = 7; 6 months male = 7; 6 months female = 6. (a) SOD1, Cu/Zn SOD, cytoplasmic isoform, 16kDa, (†*p*, age = 0.007). (b) SOD2, Mn SOD, mitochondrial isoform, 27kDa. (c) SOD3, EC SOD, extracellular isoform, 130 kDa. Analysis performed using two‐way ANOVA followed by Tukey\'s post hoc test](PHY2-8-e14440-g006){#phy214440-fig-0006}

![Urinary TBARS does not differ between sexes at either 3 or 6 months of age, *n* = 8 for all groups. Analysis performed by two‐way ANOVA followed by Tukey\'s post hoc test](PHY2-8-e14440-g007){#phy214440-fig-0007}

3.4. Female Dahl S rats maintain NO production over time while males do not {#phy214440-sec-0016}
---------------------------------------------------------------------------

The balance between ROS and NO has been cited as a key to renoprotection, since NO acts to attenuate the harmful effects of superoxide (Ratliff, Abdulmahdi, Pawar, & Wolin, [2016](#phy214440-bib-0052){ref-type="ref"}). Urinary excretion of NO metabolites (nitrate/nitrite, NOx) declines over time (*p* = .02); however, no sex differences are present (Figure [8a](#phy214440-fig-0008){ref-type="fig"}). No differences exist between sexes or ages in RNA (Figure [8b](#phy214440-fig-0008){ref-type="fig"} and Table [4](#phy214440-tbl-0004){ref-type="table"}).

![Renal NO generation is reduced in male and female rats with age (*p* = .02), despite a lack of difference in NOS3 transcription or protein expression in the renal cortex. However, there are no significant sex differences at either time point. *n* = 6--8/group. RNA and protein expression of NOS3 do not change over this time and do not differ between sexes. (A) NOx measured in urine, n/group: 3 months male = 5; 3 months female = 4; 6 months male = 5; 6 months female = 4. (b) RNA expression of NOS3 in the renal cortex, n/group: 3 months male = 4; 3 months female = 5; 6 months male = 4; 6 months female = 3. Analysis performed using two‐way ANOVA followed by Tukey\'s post hoc test](PHY2-8-e14440-g008){#phy214440-fig-0008}

4. DISCUSSION {#phy214440-sec-0017}
=============

The salient findings from this study show that there is a disparate degree of renal injury between male and female Dahl S rats despite similar systolic BP between sexes. We have shown attenuated renal injury and maintenance of renal function in female offspring supported by lower proteinuria and KIM‐1 excretion, in addition to a lack of decline in creatinine clearance by 6 months of age, as compared to age‐matched male rats. Increased urinary excretion of nephrin in male and female rats by 6 months of age confirms the progression of renal injury in this model. While we observed significantly higher mRNA levels of EC SOD in renal cortices of female rats, no difference in protein expression or oxidative stress/antioxidants was apparent. NOS3 expression and NOx excretion were similar between sexes, indicating that the NO pathway likely does not contribute to the exacerbation of renal injury and reduction in renal function with age in male Dahl SS/Jr rats.

One potential mechanism for sex differences in renal injury in Dahl S rats is the differential contribution of ROS to hypertension in male and female animals. Oxidative stress has been shown to directly contribute to hypertension in several rat models, including spontaneously hypertensive rats (SHR), stroke‐prone spontaneously hypertensive rats (SHRSP), DOCA‐salt hypertensive rats, and male Dahl S rats, with many including data that show concurrent reduction of BP when antioxidants are administered (Beswick et al., [2001](#phy214440-bib-0004){ref-type="ref"}; Grunfeld et al., [1995](#phy214440-bib-0021){ref-type="ref"}; Meng et al., [2003](#phy214440-bib-0037){ref-type="ref"}; Schnackenberg et al., [1998](#phy214440-bib-0060){ref-type="ref"}; Taylor, Glocka, Liang, & Cowley, [2006](#phy214440-bib-0065){ref-type="ref"}; Tian et al., [2007](#phy214440-bib-0066){ref-type="ref"}). However, clinical trials of antioxidant use in hypertension have yielded inconsistent results and largely focus on cardiovascular outcomes without reporting outcomes of hypertension‐induced renal disease (Czernichow et al., [2005](#phy214440-bib-0009){ref-type="ref"}; Kizhakekuttu & Widlansky, [2010](#phy214440-bib-0031){ref-type="ref"}; Ward et al., [2007](#phy214440-bib-0072){ref-type="ref"}). Most seem to be limited by the ability to achieve therapeutic levels in vivo or potential side effects, with the most promising being coenzyme Q10 (Kizhakekuttu & Widlansky, [2010](#phy214440-bib-0031){ref-type="ref"}).

The limited number of studies on hypertension in female humans and animals suggest that the etiology of disease in this sex may be more complex, possibly due to numerous sex‐specific health events such as pregnancy and menopause (Gillis & Sullivan, [2016](#phy214440-bib-0019){ref-type="ref"}; Wenger et al., [2016](#phy214440-bib-0073){ref-type="ref"}). Because epidemiologic data show an increase in hypertension in women as they age (Mozaffarian et al., [2016](#phy214440-bib-0040){ref-type="ref"}), as well as increased risk for end‐organ damage in premenopausal women (Palatini et al., [2011](#phy214440-bib-0046){ref-type="ref"}), it is important to study mechanisms of sex differences independently of BP. For example, Ji et al. ([2005](#phy214440-bib-0026){ref-type="ref"}) showed a higher degree of renal injury in male rats as compared to female rats with a similar degree of hypertension in a renal wrap model, which may be related to differences in renal NO production between the sexes. Human studies have also demonstrated that ROS are present at higher levels in males as compared to age‐matched females independent of BP (Tomomi et al., [2002](#phy214440-bib-0067){ref-type="ref"}).

Salt‐sensitive hypertension in the male Dahl S rat has been shown to cause a sharp decrease in levels of all isoforms of renal medullary SOD and increases in cortical and medullary superoxides compared to those fed a low salt (0.03% NaCl) diet, which are thought to precede elevations in MAP (Meng, Roberts, Cason, Curry, & Manning, [2002](#phy214440-bib-0038){ref-type="ref"}). Even those animals on the low‐salt diet showed decreases in renal SOD and increases in renal superoxides compared with Dahl R (salt resistant) rats, suggesting that Dahl S rats on a low‐salt diet exhibit reduction or destruction of SOD, and that further reduction of SOD may be an underlying cause of their salt sensitive hypertension (Meng et al., [2002](#phy214440-bib-0038){ref-type="ref"}). However, since these studies did not include female rats, a contribution of this mechanism to sex differences in renal injury and function could not be assessed. Our data support and add to these findings by showing age‐related increases in renal oxidative stress, which may be reflective of a decrease in cortical Cu/Zn SOD expression and increases in nephrin excretion in both sexes.

Bhatia, Elmarakby, El‐Remessy, & Sullivan ([2012](#phy214440-bib-0005){ref-type="ref"}) showed that male SHR exhibit higher levels of oxidative stress and lower antioxidant potential during Ang II‐induced hypertension, and that the male‐specific increase in BP with Ang II can be attenuated using the antioxidant apocynin. However, the key enzymatic difference in this study was in renal cortical NADPH oxidase, while SOD expression and activity were similar among groups. These data, combined with the present study, suggest that the molecular mechanisms differ among models of hypertension, in addition between sexes within the same model.

Superoxide reacts with NO at a faster rate than it does with SOD (Gryglewski, Palmer, & Moncada, [1986](#phy214440-bib-0022){ref-type="ref"}; Omar, Cherry, Mortelliti, Burke‐Wolin, & Wolin, [1991](#phy214440-bib-0042){ref-type="ref"}; Rubanyi & Vanhoutte, [1986](#phy214440-bib-0056){ref-type="ref"}). A study by Grunfeld et al. ([1995](#phy214440-bib-0021){ref-type="ref"}) in SHRSP vascular endothelial cells demonstrated that these cells produce more superoxide than those of normotensive controls and concordantly less NO, which is replenished by addition of SOD. This suggests that superoxide reduces NO levels with a contributory effect of reduction in SOD levels. Indeed, another study suggests that the mechanism of oxidative stress‐induced hypertension is via its inactivation of NO (Schnackenberg et al., [1998](#phy214440-bib-0060){ref-type="ref"}). The reaction between NO and superoxide also leads to the formation of peroxynitrite, perpetuating the cascade of endothelial dysfunction by damaging endothelial cells and preventing NO‐induced vasorelaxation (Beckman & Koppenol, [1996](#phy214440-bib-0003){ref-type="ref"}). The data shown here support the contribution of a harmful NO/ROS balance to age‐ and hypertension‐related renal injury by showing an increase in oxidative stress, reduction in Cu/Zn (cytoplasmic) SOD, and decrease in NO excretion products (NOx) from 3 to 6 months of age.

NOS3 is a major producer of NO not only in the renal vasculature as previously thought (Ujiie, Yuen, Hogarth, Danziger, & Star, [1994](#phy214440-bib-0069){ref-type="ref"}), but also in the tubules (Allcock, Hukkanen, Polak, Pollock, & Pollock, [1999](#phy214440-bib-0001){ref-type="ref"}). Upregulation of NOS3 has been shown to play a protective role against hypertensive renal damage in rodent models, including the Dahl S rat (Allcock et al., [1999](#phy214440-bib-0001){ref-type="ref"}; Tashiro, Yogo, Serizawa, & Endo, [2015](#phy214440-bib-0064){ref-type="ref"}). Furthermore, the combination of drug‐induced maintenance of NOS3 activity and reduction in ROS has been shown to protect against hypertensive end‐organ damage (Zhou et al., [2004](#phy214440-bib-0078){ref-type="ref"}). NOS3 protein expression in the renal cortex of Sprague--Dawley rats (*SD*) previously showed sex differences with age, where expression decreased significantly in males but not females (Erdely, Greenfeld, Wagner, & Baylis, [2003](#phy214440-bib-0016){ref-type="ref"}). However, we found no difference between sexes in either RNA or protein expression of NOS3, suggesting that differences in renal injury may lie downstream of NOS. The *SD* rat is a progenitor strain for both the Dahl S rat and the Dahl R rat, but the two descendant strains have also previously shown significant differences in NOS3 expression, where Dahl R rats show twice the level of NOS3 mRNA expression of Dahl S rats (Kobayashi et al., [2008](#phy214440-bib-0032){ref-type="ref"}). The current study suggests that female Dahl S rats may be better able to maintain functional production of NO, as evidenced by their maintenance of NOx excretion with age. It is also possible that the increased superoxide seen in male rats results in greater inactivation of NO with resultant decreases in NO bioavailability.

The current study exhibits an increase in transcription of EC SOD in the healthier female rats with no detectable difference in protein expression. True elevation of EC SOD resulting in increased protein expression and activity would be consistent with a response to renal damage induced by infiltrating immune cells. Upregulation of EC SOD has been shown to reduce tubulointerstitial fibrosis, as well as expression levels of profibrotic factors TGF‐β and collagen I in a model of diabetic nephropathy (Kuo et al., [2015](#phy214440-bib-0034){ref-type="ref"}). Reduced levels of EC SOD and increases in oxidative stress have also been shown to play a key role in the progression of proteinuric kidney disease in several animal models, including ADR‐induced nephropathy, Ang II‐induced renal injury, and albumin‐overload proteinuria (Tan et al., [2015](#phy214440-bib-0062){ref-type="ref"}). However, the difference we saw in EC SOD RNA did not result in a similar difference in protein expression of EC SOD in the renal cortex. EC SOD undergoes significant posttranslational modification, including C‐terminal processing and N‐glycosylation, which is necessary to its secretion and function (Olsen et al., [2004](#phy214440-bib-0041){ref-type="ref"}; Ota, Kizuka, Kitazume, Adachi, & Taniguchi, [2016](#phy214440-bib-0044){ref-type="ref"}). One possibility for the results we show is that even though male rats seem to exhibit similar protein expression of EC SOD as females, there could be some processing defect that prevents modification necessary for secretion and effective action of EC SOD in the renal cortex. Conversely, there could also be increased proteolytic cleavage of EC SOD, preventing its secretion and altering tissue distribution of the enzyme.

While the tail cuff method used in these studies provided an opportunity to measure large groups of animals repeatedly and noninvasively, tail cuff readings are likely less sensitive than telemetry and the restraints necessary to tail cuff measurement provide additional stress to the animals not seen in a telemetry setting. There is also a historically consistent difficulty in accurately assessing the NO production and activity, the level of oxidative stress, and the physiologic capability to mediate oxidative stress within the kidney. The short half‐lives of NO and many markers of oxidative stress yield an unavoidable level of inaccuracy in most or all available assays. While enzyme expression levels can yield an idea of the kidney\'s response to hypertension and renal injury, this does not always correlate with activity levels, and activity levels do not always correlate with functional effects, due to increases in degradation or other physiologic interference. Another limitation is the fact that the 3‐ and 6‐month groups consisted of different animals (i.e., a single animal was not followed through all time points), a limitation necessitated to obtain blood and renal tissue at each time point. However, future studies will aim to track the renal function of individual animals over the course of time. Based on these results, we suggest that a reduced NO: ET‐1 balance in male rats contributes to the observed sex differences in renal injury and function. Further study of these differences in animal models of hypertensive kidney disease is necessary to determine the true mechanism of preserved renal function in female animals.

4.1. Perspectives {#phy214440-sec-0018}
-----------------

The Dahl S rat is an established model of salt‐sensitive hypertension and chronic kidney disease (CKD) (Dahl & Schackow, [1964](#phy214440-bib-0010){ref-type="ref"}; Tanada et al., [2017](#phy214440-bib-0063){ref-type="ref"}), as well as spontaneous, superimposed preeclampsia (Gillis, Williams, Garrett, Mooney, & Sasser, [2015](#phy214440-bib-0020){ref-type="ref"}) that develops hypertension with age in the absence of high salt. While short term and chronic effects of hypertension and CKD have been studied in this model, little has been demonstrated regarding the sex differences present in the Dahl S rat. Sex differences are well established in both human patients with hypertension (Wenger et al., [2016](#phy214440-bib-0073){ref-type="ref"}) and in several animal models of hypertension (Crofton & Share, [1997](#phy214440-bib-0008){ref-type="ref"}; Haywood & Hinojosa‐Laborde, [1997](#phy214440-bib-0023){ref-type="ref"}; Reckelhoff, [2001](#phy214440-bib-0053){ref-type="ref"}; Rowland & Fregly, [1992](#phy214440-bib-0055){ref-type="ref"}; Xue et al., [2005](#phy214440-bib-0076){ref-type="ref"}), and are theorized to contribute heavily to the etiologies of various forms of hypertension (Gillis & Sullivan, [2016](#phy214440-bib-0019){ref-type="ref"}). Women with chronic hypertension have a odds ratio of developing superimposed preeclampsia of 10.07 as compared to the risk of preeclampsia in their normotensive peers (Bateman et al., [2012](#phy214440-bib-0002){ref-type="ref"}). Therefore, elucidation of sex differences in our model of hypertension and CKD will lead to new insights on the etiology of hypertensive renal injury and hopefully to factors that predispose such women to the development of further disease such as preeclampsia. We also observed increasing oxidative stress in both sexes with age; however, clinical trials studying antioxidants in the treatment of hypertension have yielded mixed results (Czernichow et al., [2005](#phy214440-bib-0009){ref-type="ref"}; Schneider et al., [2005](#phy214440-bib-0061){ref-type="ref"}; Ward et al., [2007](#phy214440-bib-0072){ref-type="ref"}), likely due to variability in employed methods, and are not structured to compare results between sexes. Therefore, continued study is required to determine the exact contribution of these pathways to sex differences in hypertension.
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